Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep;35(9):3676-3685.
doi: 10.1007/s11695-025-08054-6. Epub 2025 Jul 25.

Evaluating Weight Loss Associated with Bariatric Surgery After Liraglutide Use: A Matched Population-Level Retrospective Cohort Study

Muhammad Faran  1 , Emma K O'Callaghan  2 , Tyler McKechnie  2 , Karen Barlow  1   3 , Olivia Kuszaj  2 , Jean-Éric Tarride  4 , Mehran Anvari  1   3 , Aristithes G Doumouras  5   6
Affiliations

Evaluating Weight Loss Associated with Bariatric Surgery After Liraglutide Use: A Matched Population-Level Retrospective Cohort Study

Muhammad Faran et al. Obes Surg. 2025 Sep.

Abstract

Introduction: Glucagon-like peptide 1 (GLP-1) analogues are an emerging class of medications used to treat obesity. While studies show that postoperative liraglutide use is an effective adjunct treatment for patients with unsuccessful weight loss after bariatric surgery, the impact of preoperative liraglutide use on postoperative outcomes remains poorly understood. Therefore, the aim of this study was to determine if postoperative weight loss and comorbidity outcomes differ for patients who use liraglutide before their bariatric surgery.

Methods: Using data from the Ontario Bariatric Registry (OBR), we conducted a retrospective, matched cohort study of patients who underwent a primary bariatric procedure between January 2010 and June 2020. Liraglutide naive patients were matched with preoperative liraglutide users. The primary outcome of interest was percentage total body weight lost (TWL) from baseline to 1-year post-surgery.

Results: A total of 1383 liraglutide naive patients were successfully matched to 449 liraglutide users at a ratio of 3:1. 1-year post-surgery; there were differences observed between groups in the primary outcome examined, with a higher TWL observed in the liraglutide naive group (27.52 ± 10.28% liraglutide naive vs. 25.46 ± 9.04% liraglutide users, p < 0.001).

Conclusions: While an increase in weight loss was observed in liraglutide naive patients, both groups had clinically significant weight loss and similar BMIs at 1-year post-surgery. This suggests that preoperative GLP-1 analogue users and GLP-1 analogue naive patients both benefit substantially from bariatric surgery.

Keywords: Bariatric surgery; Glp-1 analogues; Liraglutide; Obesity; Weight loss.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics Approval: All procedures performed involving human participants were in accordance with the ethical standards of the institutional research committee. For this type of study, formal consent is not required. Conflict of interest: The authors declare no competing interests.

References

    1. World Obesity Federation World Obesity Atlas 2023
    1. Abdullah A, Peeters A, de Courten M, et al. The magnitude of association between overweight and obesity and the risk of diabetes: a meta-analysis of prospective cohort studies. Diabetes Res Clin Pract. 2010;89:309–19. https://doi.org/10.1016/j.diabres.2010.04.012 . - DOI - PubMed
    1. Cercato C, Fonseca FA. Cardiovascular risk and obesity. Diabetol Metab Syndr. 2019;11:74. https://doi.org/10.1186/s13098-019-0468-0 . - DOI - PubMed - PMC
    1. De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obesity. 2013;2013:1–11. https://doi.org/10.1155/2013/291546 . - DOI
    1. Bour ES. Evidence supporting the need for bariatric surgery to address the obesity epidemic in the United States. Curr Sports Med Rep. 2015;14:100–3. https://doi.org/10.1249/JSR.0000000000000135 . - DOI - PubMed